ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet2015418-22ometendo-7831Research ArticleОбзор литературыReviewПрименение Ксеникала в клинической практикеXenical in clinical practiceЕршоваЕкатерина ВладимировнаErshovaEkaterina Vladimirovna

научный сотрудник отделения терапии с группой ожирения

yu99pol06@rambler.ruТрошинаЕкатерина АнатольевнаTroshinaEkaterina Anatol'evna

д.м.н., профессор, заведующая отделением терапии с группой ожирения

troshina@inbox.ruКомшиловаКсения АндреевнаKomshilovaKseniya Andreevna

научный сотрудник отделения терапии с группой ожирения

kom-ksusha@rambler.ruФГБУ Эндокринологический научный центр Минздрава РоссииРоссияEndocrinology Research CentreRussian Federation2015090320161241822Copyright © Ершова Е.В., Трошина Е.А., Комшилова К.А., 20152015Ершова Е.В., Трошина Е.А., Комшилова К.А.Ershova E.V., Troshina E.A., Komshilova K.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/7831

The basis of the treatment of obesity is changing eating pattern, combined with increased physical activity. However, not all patients can change their eating habits and lifestyle. This dictates a necessity to include pharmacotherapy in complex treatment of obesity. Currently, the drug of choice for the treatment of patients with complicated obesity is orlistat – peripheral drug, which exert its therapeutic effect within the gastrointestinal tract and has no systemic actions.

ожирениелечениепитаниефизическая активностьорлистат.obesitytreatmentnutritionphysical activityorlistatReferencesБутрова С. А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению //Русский медицинский журнал. – 2001. – Т. 9. – №. 2. – С. 56-60. [Butrova S A Metabolicheskiy sindrom: patogenez, klinika, diagnostika, podkhody k lecheniyu. Russkiy meditsinskiy zhurnal. 2001; 9(2): 56-60. (In Russ).].Бутрова С. А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению //Русский медицинский журнал. – 2001. – Т. 9. – №. 2. – С. 56-60. [Butrova S A Metabolicheskiy sindrom: patogenez, klinika, diagnostika, podkhody k lecheniyu. Russkiy meditsinskiy zhurnal. 2001; 9(2): 56-60. (In Russ).].Мкртумян А.М. Ксеникал в комплексной терапии метаболического синдрома // Русский медицинский журнал. — 2001. – Т. 9. – №. 2.— С. 72–73. [Mkrtumyan AM. Ksenikal v kompleksnoy terapii metabolicheskogo sindroma. Russkiy meditsinskiy zhurnal. 2001; 9(2): 72–73. (In Russ).]Мкртумян А.М. Ксеникал в комплексной терапии метаболического синдрома // Русский медицинский журнал. — 2001. – Т. 9. – №. 2.— С. 72–73. [Mkrtumyan AM. Ksenikal v kompleksnoy terapii metabolicheskogo sindroma. Russkiy meditsinskiy zhurnal. 2001; 9(2): 72–73. (In Russ).]Чигарькова О.В. Состояние костной ткани у женщин с ожирением в постменопаузе. Влияние снижения массы тела на минеральную плотность кости и показатели костного метаболизма : дис. … канд. мед. наук. — М., 2008. — С. 138. [Chigar'kova OV. Sostoyanie kostnoy tkani u zhenshchin s ozhireniem v postmenopauze. Vliyanie snizheniya massy tela na mineral'nuyu plotnost' kosti i pokazateli kostnogo metabolizma.[dissertation] Moscow; 2008. (In Russ)]Чигарькова О.В. Состояние костной ткани у женщин с ожирением в постменопаузе. Влияние снижения массы тела на минеральную плотность кости и показатели костного метаболизма : дис. … канд. мед. наук. — М., 2008. — С. 138. [Chigar'kova OV. Sostoyanie kostnoy tkani u zhenshchin s ozhireniem v postmenopauze. Vliyanie snizheniya massy tela na mineral'nuyu plotnost' kosti i pokazateli kostnogo metabolizma.[dissertation] Moscow; 2008. (In Russ)]Butrova S., Ershova E., Ilyin A. et al. Orlistat influence on clinical, hormonal and metabolic parameters of obese patients with high risk of type 2 diabetes and cardiovascular diseases. Int. J. Obes. 2004; 28: 115.Butrova S., Ershova E., Ilyin A. et al. Orlistat influence on clinical, hormonal and metabolic parameters of obese patients with high risk of type 2 diabetes and cardiovascular diseases. Int. J. Obes. 2004; 28: 115.Cocco G, Pandolfi S, Rousson V. Sufficient Weight Reduction Decreases Cardiovascular Complications in Diabetic Patients with the Metabolic Syndrome. Heart Drug. 2005;5(2):68-74. doi: 10.1159/000083662Cocco G, Pandolfi S, Rousson V. Sufficient Weight Reduction Decreases Cardiovascular Complications in Diabetic Patients with the Metabolic Syndrome. Heart Drug. 2005;5(2):68-74. doi: 10.1159/000083662Colditz GA. Weight Gain as a Risk Factor for Clinical Diabetes Mellitus in Women. Annals of Internal Medicine. 1995;122(7):481. doi: 10.7326/0003-4819-122-7-199504010-00001Colditz GA. Weight Gain as a Risk Factor for Clinical Diabetes Mellitus in Women. Annals of Internal Medicine. 1995;122(7):481. doi: 10.7326/0003-4819-122-7-199504010-00001Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With Orlistat. Jama. 1999;281(3):235. doi: 10.1001/jama.281.3.235Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With Orlistat. Jama. 1999;281(3):235. doi: 10.1001/jama.281.3.235Didangelos TP, Thanopoulou AK, Bousboulas SH, Sambanis CL, Athyros VG, Spanou EA, et al. The ORlistat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORliCARDIA) study. Current Medical Research and Opinion. 2004;20(9):1393-401. doi: 10.1185/030079904125004466Didangelos TP, Thanopoulou AK, Bousboulas SH, Sambanis CL, Athyros VG, Spanou EA, et al. The ORlistat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORliCARDIA) study. Current Medical Research and Opinion. 2004;20(9):1393-401. doi: 10.1185/030079904125004466Dimitrov D, Bohchelian H, Koeva L. Effect of Orlistat on Plasma Leptin Levels and Risk Factors for the Metabolic Syndrome. Metabolic Syndrome and Related Disorders. 2005;3(2):122-9. doi: 10.1089/met.2005.3.122Dimitrov D, Bohchelian H, Koeva L. Effect of Orlistat on Plasma Leptin Levels and Risk Factors for the Metabolic Syndrome. Metabolic Syndrome and Related Disorders. 2005;3(2):122-9. doi: 10.1089/met.2005.3.122Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. The Lancet. 1998;352(9123):167-72. doi: 10.1016/s0140-6736(97)11509-4Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. The Lancet. 1998;352(9123):167-72. doi: 10.1016/s0140-6736(97)11509-4Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Current Medical Research and Opinion. 2005;21(12):1997-2006. doi: 10.1185/030079905x75078Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Current Medical Research and Opinion. 2005;21(12):1997-2006. doi: 10.1185/030079905x75078Finer N, James WPT, Kopelman PG, Lean MEJ, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. International Journal of Obesity. 2000;24(3):306-13. doi: 10.1038/sj.ijo.0801128Finer N, James WPT, Kopelman PG, Lean MEJ, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. International Journal of Obesity. 2000;24(3):306-13. doi: 10.1038/sj.ijo.0801128Gotfredsen A, Westergren Hendel H, Andersen T. Influence of orlistat on bone turnover and body composition. International Journal of Obesity. 2001;25(8):1154-60. doi: 10.1038/sj.ijo.0801639Gotfredsen A, Westergren Hendel H, Andersen T. Influence of orlistat on bone turnover and body composition. International Journal of Obesity. 2001;25(8):1154-60. doi: 10.1038/sj.ijo.0801639Hauptman J. Orlistat in the Long-term Treatment of Obesity in Primary Care Settings. Archives of Family Medicine. 2000;9(2):160-7. doi: 10.1001/archfami.9.2.160Hauptman J. Orlistat in the Long-term Treatment of Obesity in Primary Care Settings. Archives of Family Medicine. 2000;9(2):160-7. doi: 10.1001/archfami.9.2.160Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, et al. Effects of Weight Loss With Orlistat on Glucose Tolerance and Progression to Type 2 Diabetes in Obese Adults. Archives of Internal Medicine. 2000;160(9):1321. doi: 10.1001/archinte.160.9.1321Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, et al. Effects of Weight Loss With Orlistat on Glucose Tolerance and Progression to Type 2 Diabetes in Obese Adults. Archives of Internal Medicine. 2000;160(9):1321. doi: 10.1001/archinte.160.9.1321Hill JO. Obesity and the Environment: Where Do We Go from Here? Science. 2003;299(5608):853-5. doi: 10.1126/science.1079857Hill JO. Obesity and the Environment: Where Do We Go from Here? Science. 2003;299(5608):853-5. doi: 10.1126/science.1079857Hill, J. O., Hauptman, J., Anderson, J. W., Fujioka, K., O'Neil, P. M., Smith, D. K., ... & Aronne, L. J. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. The American journal of clinical nutrition. 1999; 69(6), 1108-1116.Hill, J. O., Hauptman, J., Anderson, J. W., Fujioka, K., O'Neil, P. M., Smith, D. K., ... & Aronne, L. J. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. The American journal of clinical nutrition. 1999; 69(6), 1108-1116.Holecki M, Zahorska-Markiewicz B, Nieszporek T, Mizia-Stec K, Olszanecka-Glinianowicz M, Żak-Gołąb A, et al. Impact of the mass-reductive therapy with orlistat on 25-(OH)-D 3 and PTH concentration in sera of obese, menopausal women. Endokrynologia Polska. 2005;56(3):240-5.Holecki M, Zahorska-Markiewicz B, Nieszporek T, Mizia-Stec K, Olszanecka-Glinianowicz M, Żak-Gołąb A, et al. Impact of the mass-reductive therapy with orlistat on 25-(OH)-D 3 and PTH concentration in sera of obese, menopausal women. Endokrynologia Polska. 2005;56(3):240-5.Krempf M., Laville M., Basdevant A. et al. Effect of orlistat on NCEP ATP-III-defined metabolic syndrome in obese or overweight patients: meta-analysis from 20 randomised double-blind studies worldwide. Obes. Rev. 2005; 1: 166.Krempf M., Laville M., Basdevant A. et al. Effect of orlistat on NCEP ATP-III-defined metabolic syndrome in obese or overweight patients: meta-analysis from 20 randomised double-blind studies worldwide. Obes. Rev. 2005; 1: 166.Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2003;27(1):155-61. doi: 10.2337/diacare.27.1.155Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2003;27(1):155-61. doi: 10.2337/diacare.27.1.155Wirth A. Reduction of body weight and co-morbidities by orlistat: The XXL – Primary Health Care Trial. Diabetes, Obesity and Metabolism. 2005;7(1):21-7. doi: 10.1111/j.1463-1326.2004.00428.xWirth A. Reduction of body weight and co-morbidities by orlistat: The XXL – Primary Health Care Trial. Diabetes, Obesity and Metabolism. 2005;7(1):21-7. doi: 10.1111/j.1463-1326.2004.00428.x

The authors declare that there are no conflicts of interest present.